Skandinaviska Enskilda Banken AB publ Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Skandinaviska Enskilda Banken AB publ bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 26,816 shares of the company’s stock, valued at approximately $634,000.

A number of other large investors also recently modified their holdings of the business. Swiss National Bank raised its position in shares of Dyne Therapeutics by 3.3% during the 4th quarter. Swiss National Bank now owns 108,600 shares of the company’s stock worth $2,559,000 after purchasing an additional 3,500 shares during the period. Lisanti Capital Growth LLC increased its position in Dyne Therapeutics by 233.7% in the fourth quarter. Lisanti Capital Growth LLC now owns 57,755 shares of the company’s stock worth $1,361,000 after buying an additional 40,445 shares during the period. E Fund Management Co. Ltd. lifted its stake in Dyne Therapeutics by 11.8% in the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company’s stock valued at $279,000 after buying an additional 1,249 shares during the last quarter. Candriam S.C.A. boosted its holdings in shares of Dyne Therapeutics by 2.7% during the fourth quarter. Candriam S.C.A. now owns 401,395 shares of the company’s stock valued at $9,457,000 after acquiring an additional 10,439 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Dyne Therapeutics during the fourth quarter worth about $2,340,000. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Price Performance

DYN stock opened at $12.31 on Tuesday. The firm has a market capitalization of $1.39 billion, a P/E ratio of -3.46 and a beta of 1.11. Dyne Therapeutics, Inc. has a 52-week low of $11.18 and a 52-week high of $47.45. The company’s 50 day simple moving average is $14.33 and its 200-day simple moving average is $24.90.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. Sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Buying and Selling

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 6,237 shares of company stock valued at $77,760. Corporate insiders own 20.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on DYN. Robert W. Baird assumed coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 target price for the company. Piper Sandler decreased their price objective on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Scotiabank started coverage on Dyne Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price on the stock. Chardan Capital restated a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Monday. Finally, Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $48.85.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.